Literature DB >> 16046400

Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes.

April M Shiflett1, Joseph R Bishop, Amit Pahwa, Stephen L Hajduk.   

Abstract

Human innate immunity to non-pathogenic species of African trypanosomes is provided by human high density lipoprotein (HDL) particles. Here we show that native human HDLs containing haptoglobin-related protein (Hpr), apolipoprotein L-I (apoL-I) and apolipoprotein A-I (apoA-I) are the principle antimicrobial molecules providing protection from trypanosome infection. Other HDL subclasses containing either apoA-I and apoL-I or apoA-I and Hpr have reduced trypanolytic activity, whereas HDL subclasses lacking apoL-I and Hpr are non-toxic to trypanosomes. Highly purified, lipid-free Hpr and apoL-I were both toxic to Trypanosoma brucei brucei but with specific activities at least 500-fold less than those of native HDLs, suggesting that association of these apolipoproteins within the HDL particle was necessary for optimal cytotoxicity. These studies show that HDLs can serve as platforms for the assembly of multiple synergistic proteins and that these assemblies may play a critical role in the evolution of primate-specific innate immunity to trypanosome infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046400     DOI: 10.1074/jbc.M503510200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

Review 1.  Antimicrobial peptide killing of African trypanosomes.

Authors:  J M Harrington
Journal:  Parasite Immunol       Date:  2011-08       Impact factor: 2.280

2.  Putting sleeping sickness to bed.

Authors:  Cassandra Willyard
Journal:  Nat Med       Date:  2011-01       Impact factor: 53.440

3.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

Authors:  Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

4.  HDL proteomics: pot of gold or Pandora's box?

Authors:  Muredach P Reilly; Alan R Tall
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 5.  The protein cargo of HDL: implications for vascular wall biology and therapeutics.

Authors:  Jay W Heinecke
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

6.  The HDL proteome: a marker--and perhaps mediator--of coronary artery disease.

Authors:  Jay W Heinecke
Journal:  J Lipid Res       Date:  2008-12-05       Impact factor: 5.922

Review 7.  Thematic review series: proteomics. Proteomic analysis of lipid-protein complexes.

Authors:  Tomas Vaisar
Journal:  J Lipid Res       Date:  2009-02-19       Impact factor: 5.922

8.  Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks.

Authors:  Nicholas M Frame; Olga Gursky
Journal:  FEBS Lett       Date:  2016-03-06       Impact factor: 4.124

9.  Apolipoprotein A-I binding to anionic vesicles and lipopolysaccharides: role for lysine residues in antimicrobial properties.

Authors:  Wendy H J Beck; Christopher P Adams; Ivan M Biglang-Awa; Arti B Patel; Heather Vincent; Eric J Haas-Stapleton; Paul M M Weers
Journal:  Biochim Biophys Acta       Date:  2013-02-26

10.  Evolution of the primate trypanolytic factor APOL1.

Authors:  Russell Thomson; Giulio Genovese; Chelsea Canon; Daniella Kovacsics; Matthew K Higgins; Mark Carrington; Cheryl A Winkler; Jeffrey Kopp; Charles Rotimi; Adebowale Adeyemo; Ayo Doumatey; George Ayodo; Seth L Alper; Martin R Pollak; David J Friedman; Jayne Raper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.